ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,798.60
-0.23%
Gold vs US Dollar
2,293.815
-3.49%
Brent Oil
79.335
-0.68%
Bitcoin
69,164.48
-2.27%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acorda Therapeutics Inc (ACOR)

  7. Acorda Therapeutics Inc (ACOR) News

Acorda Therapeutics (ACOR)

Acorda Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACOR
DateTimeSourceHeadlineSymbolCompany
15/04/202422:03Business WireAcorda Therapeutics Announces Delisting from NasdaqNASDAQ:ACORAcorda Therapeutics Inc
03/04/202422:30Business WireAcorda Therapeutics Announces Nasdaq Delisting NotificationNASDAQ:ACORAcorda Therapeutics Inc
01/04/202423:35Business WireAcorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase AgreementNASDAQ:ACORAcorda Therapeutics Inc
01/04/202421:01Business WireAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024NASDAQ:ACORAcorda Therapeutics Inc
25/03/202420:01Business WireAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024NASDAQ:ACORAcorda Therapeutics Inc
11/01/202413:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
11/01/202413:01Business WireAcorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025NASDAQ:ACORAcorda Therapeutics Inc
01/12/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
13/11/202321:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
13/11/202321:01Business WireAcorda Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:ACORAcorda Therapeutics Inc
06/11/202321:01Business WireAcorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023NASDAQ:ACORAcorda Therapeutics Inc
06/11/202313:00Business WireAcorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®NASDAQ:ACORAcorda Therapeutics Inc
08/08/202321:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
08/08/202321:01Business WireAcorda Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ACORAcorda Therapeutics Inc
02/08/202313:00Business WireAcorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”NASDAQ:ACORAcorda Therapeutics Inc
01/08/202313:00Business WireAcorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023NASDAQ:ACORAcorda Therapeutics Inc
28/06/202322:08Business WireTom Burns Elected to the Acorda Therapeutics Board of DirectorsNASDAQ:ACORAcorda Therapeutics Inc
26/06/202321:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
26/06/202313:23Business WireAcorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ACORAcorda Therapeutics Inc
26/06/202313:00Business WireAcorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price RequirementNASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:37Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
02/06/202321:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
02/06/202321:01Business WireAcorda Therapeutics Announces Completion of 1-for-20 Reverse Stock SplitNASDAQ:ACORAcorda Therapeutics Inc
01/06/202322:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
31/05/202322:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
31/05/202321:01Business WireAcorda Therapeutics to Conduct 1-for-20 Reverse Stock SplitNASDAQ:ACORAcorda Therapeutics Inc
30/05/202313:00Business WireAcorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&ANASDAQ:ACORAcorda Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACOR

Your Recent History

LSE
GDR
Genedrive
LSE
PANR
Pantheon Resources
LSE
BP.
Bp
LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
LLOY
Lloyds Banking
LSE
GGP
Greatland Gold
LSE
EUA
Eurasia Mining
LSE
EEE
Empire Metals
LSE
SRT
Srt Marine Systems
LSE
PFC
Petrofac
LSE
TERN
Tern
LSE
AAZ
Anglo Asian Mining
LSE
I3E
I3 Energy
LSE
GKP
Gulf Keystone Petroleum
LSE
BIRD
Blackbird
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved